Results 81 to 90 of about 34,322 (240)

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

Defining medication adherence in individual patients

Patient Preference and Adherence, 2015
Alan Morrison, Melissa E Stauffer, Anna S Kaufman ScribCo, Effort, PA, USA Background: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken ...
Morrison A, Stauffer ME, Kaufman AS
doaj  

Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Paradoxical atopic dermatitis (AD) can arise during biologic therapy for psoriasis due to an immune‐axis imbalance. We describe a 47‐year‐old man who developed severe AD while receiving secukinumab, which was successfully managed with the addition of dupilumab, allowing long‐term control of both diseases.
So Yun Park, Minjung Park, Ho Eun Gwang, Narang Hong, Hye Jung Jung, Mi Youn Park, Jiyoung Ahn   +6 more
wiley   +1 more source

Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study

Journal of Dermatological Treatment
Background The advent of biosimilars may increase the frequency of dose escalation with biologics in psoriasis.Objective To explore the frequency and outcomes of dose escalation with adalimumab etanercept, and ustekinumab.Methods Data were extracted from
Axel Svedbom, Christina Wennerström, Fredrik Hjelm, Anna Tjärnlund, Mona Ståhle   +4 more
doaj   +1 more source

A Cross‐Sectional Survey Study Assessing the Quality of Life and Sleep in Spanish Psoriasis Patients

JEADV Clinical Practice, EarlyView.
Psoriasis impacts quality of life (QOL) and sleep (QOS), yet dermatology assessments often do not evaluate sleep. The Short‐form health survey (SF‐36) and Pittsburg sleep quality index (PSQI) further investigated patients’ QOL and QOS. Particularly women, unemployed patients, and those that use sleep medications had worse QOS and QOL.
Gabriela Piñero‐Crespo, María Isabel del Pino Rincón, Lilia Correa‐Selm, Raquel Hernández Sánchez, Amalia Pérez‐Gil   +4 more
wiley   +1 more source

Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange, Tara Sholji, Marra Aghajani, Cindy Kok, John Frew   +4 more
wiley   +1 more source

Therapeutic Challenges in Managing Coexisting Hidradenitis Suppurativa and Squamous Cell Carcinoma: A Clinical Case Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting intertriginous areas. Long‐standing HS can undergo malignant transformation into squamous cell carcinoma (SCC), particularly in the perineal and gluteal regions. We report a 54‐year‐old man with severe, treatment‐refractory HS complicated by an aggressive verrucous
Michael Zolotas, Tereza Jakovljevicova, Kamran Ghoreschi, Kerstin Kusch, Marisa Klemp, Robert Sabat, Georgios Kokolakis   +6 more
wiley   +1 more source

The Effects of Biologic Agents on Carotid Intima‐Media Thickness and Hepatic Steatosis in Patients With Moderate‐To‐Severe Psoriasis: A Prospective Observational Cohort Study

JEADV Clinical Practice, EarlyView.
In this prospective observational cohort study, 34 patients with moderate‐to‐severe psoriasis received biologic therapy (anti‐TNF‐α, anti‐IL‐12/23, or anti‐IL‐17) for 6 months. Carotid intima–media thickness decreased significantly in the overall cohort (p < 0.01), with the greatest reductions in the anti‐IL‐17 and anti‐IL‐12/23 groups.
Harika Ödemiş, Burçe Can Kuru, Bilal Doğan, Ceyda Civan Kuş, Mehmethan Çelik, Nurhilal Kızıltoprak, Fatih Özçelik   +6 more
wiley   +1 more source

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

RMD Open
Objectives Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk.Methods In SELECT-COMPARE, patients received upadacitinib ...
Roy Fleischmann, Stephen Hall, Gerd R Burmester, Eduardo Mysler, Peter Taylor, Tianming Gao, Sander Strengholt, Bettina Wick-Urban, Andrew Garrison, Irina Fish   +9 more
doaj   +1 more source

Impact of BMI and Body Weight on Clinical Outcomes in Psoriasis: A Post Hoc Analysis of the RESOLVE Observational Study

JEADV Clinical Practice, EarlyView.
This post‐hoc analysis of the Greek real‐world ReSOLVE study compared clinical and patient‐reported outcomes by body weight (< 100 kg vs. ≥ 100 kg) and BMI over 52 weeks. Patients ≥ 100 kg showed delayed PASI and sPGA responses at W24 and W52, while BMI had little impact. Quality‐of‐life improvements were substantial, though early gains were smaller in
Pantelis Panagakis, Kanella Kalapothakou, Despina Exadactylou, Ioanna Lefaki, Marina Papoutsaki, Natalia Rompoti, Dimitrios Xekardakis, Nikolaos Fekkas, Efthymios Stathatos, Athanasios Chaniotis, Electra Nicolaidou, Alexandros Stratigos, Vasiliki Chasapi   +12 more
wiley   +1 more source